Citigroup
LBRX

Citigroup’s LB Pharmaceuticals LBRX Stock Holding History

Citigroup’s Portfolio LBRX Stock Details LBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$510K Buy
15,719
+10,150
+182% +$298K ﹤0.01% 3887
2026
Q1 		$137K Buy
5,569
+5,134
+1,180% +$118K ﹤0.01% 4164
2025
Q4 		$9.68K Buy
+435
New +$7.6K ﹤0.01% 5068

Other funds holding LBRX

DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Citigroup's LBRX Position: Q2 2026 in Review

Citigroup increased its LB Pharmaceuticals (LBRX) stake by 182% in Q2 2026, buying an estimated $298K and bringing the position to 15,719 shares worth $510K. The position accounts for ﹤0.01% of the portfolio, ranked #3887.

Citigroup first reported a position in LBRX in Q4 2025 and has held it in 3 quarters since. 114 funds tracked by Wall St. Rank hold LBRX as of Q2 2026.

  • Citigroup held 15,719 shares of LB Pharmaceuticals worth $510K as of Q2 2026.
  • Citigroup bought 10,150 LB Pharmaceuticals shares in Q2 2026, an estimated $298K.
  • LB Pharmaceuticals made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #3887 holding.
  • Citigroup first reported a position in LB Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 114 funds tracked by Wall St. Rank held LB Pharmaceuticals as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.